Literature DB >> 16149064

Combined genome-wide allelotyping and copy number analysis identify frequent genetic losses without copy number reduction in medulloblastoma.

Jacqueline A Langdon1, Jayne M Lamont, Debbie K Scott, Sara Dyer, Emma Prebble, Nick Bown, Richard G Grundy, David W Ellison, Steven C Clifford.   

Abstract

Detailed analysis of mechanisms of genetic loss for specific tumor suppressor genes (TSGs; e.g., RB1, APC and NF1) indicates that TSG inactivation can occur by allelic loss of heterozygosity (LOH), without any alteration in DNA copy number. However, the role and prevalence of such events in the pathogenesis of specific malignancies remains to be established on a genome-wide basis. We undertook a detailed molecular assessment of chromosomal defects in a panel of nine cell lines derived from primary medulloblastomas, the most common malignant brain tumors of childhood, by parallel genome-wide assessment of LOH (allelotyping) and copy number aberrations (comparative genomic hybridization and fluorescence in situ hybridization). The majority of genetic losses observed were detected by both copy number and LOH methods, indicating they arise through the physical deletion of chromosomal material. However, a significant proportion of losses (17/42, 40%) represented regions of allelic LOH without any associated copy number reduction; these events involved both whole chromosomes (10/17) and sub-chromosomal regions (7/17). Using this approach, we identified medulloblastoma-characteristic alterations, e.g., isochromosome for 17q, MYC amplification and losses on chromosomes 10, 11, and 16, alongside novel regions of genetic loss (e.g., 10q21.1-26.3, 11q24.1-qter). This detailed genetic characterization of the majority of medulloblastoma cell lines provides important precedent for the widespread involvement of copy number-neutral genetic losses in medulloblastoma and demonstrates that combined assessment of copy number aberrations and LOH will be necessary to accurately determine the contribution of chromosomal defects to tumor development. Copyright 2005 Wiley-Liss, Inc

Entities:  

Mesh:

Year:  2006        PMID: 16149064     DOI: 10.1002/gcc.20262

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  19 in total

1.  RNA-mediated epigenetic regulation of DNA copy number.

Authors:  Mariusz Nowacki; Joanna E Haye; Wenwen Fang; Vikram Vijayan; Laura F Landweber
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-15       Impact factor: 11.205

2.  High-resolution genomic profiling of chromosomal aberrations using Infinium whole-genome genotyping.

Authors:  Daniel A Peiffer; Jennie M Le; Frank J Steemers; Weihua Chang; Tony Jenniges; Francisco Garcia; Kirt Haden; Jiangzhen Li; Chad A Shaw; John Belmont; Sau Wai Cheung; Richard M Shen; David L Barker; Kevin L Gunderson
Journal:  Genome Res       Date:  2006-08-09       Impact factor: 9.043

3.  Clinical, radiological, histological and molecular characteristics of paediatric epithelioid glioblastoma.

Authors:  A Broniscer; R G Tatevossian; N D Sabin; P Klimo; J Dalton; R Lee; A Gajjar; D W Ellison
Journal:  Neuropathol Appl Neurobiol       Date:  2014-04       Impact factor: 8.090

4.  DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies.

Authors:  Edward C Schwalbe; Daniel Williamson; Janet C Lindsey; Dolores Hamilton; Sarra L Ryan; Hisham Megahed; Miklós Garami; Peter Hauser; Bożena Dembowska-Baginska; Danuta Perek; Paul A Northcott; Michael D Taylor; Roger E Taylor; David W Ellison; Simon Bailey; Steven C Clifford
Journal:  Acta Neuropathol       Date:  2013-01-05       Impact factor: 17.088

5.  Neuralized1 causes apoptosis and downregulates Notch target genes in medulloblastoma.

Authors:  Natalia Teider; Deborah K Scott; Adrianne Neiss; S Dilhan Weeraratne; Vladimir M Amani; Yifei Wang; Victor E Marquez; Yoon-Jae Cho; Scott L Pomeroy
Journal:  Neuro Oncol       Date:  2010-09-16       Impact factor: 12.300

6.  Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699.

Authors:  R A Daniel; A L Rozanska; E A Mulligan; Y Drew; H D Thomas; D J Castelbuono; Z Hostomsky; E R Plummer; D A Tweddle; A V Boddy; S C Clifford; N J Curtin
Journal:  Br J Cancer       Date:  2010-10-26       Impact factor: 7.640

7.  Genomic analysis using high-density single nucleotide polymorphism-based oligonucleotide arrays and multiplex ligation-dependent probe amplification provides a comprehensive analysis of INI1/SMARCB1 in malignant rhabdoid tumors.

Authors:  Eric M Jackson; Angela J Sievert; Xiaowu Gai; Hakon Hakonarson; Alexander R Judkins; Laura Tooke; Juan Carlos Perin; Hongbo Xie; Tamim H Shaikh; Jaclyn A Biegel
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

8.  Prevalence of copy-number neutral LOH in glioblastomas revealed by genomewide analysis of laser-microdissected tissues.

Authors:  Daisuke Kuga; Masahiro Mizoguchi; Yanlei Guan; Nobuhiro Hata; Koji Yoshimoto; Tadahisa Shono; Satoshi O Suzuki; Yoji Kukita; Tomoko Tahira; Shinji Nagata; Tomio Sasaki; Kenshi Hayashi
Journal:  Neuro Oncol       Date:  2008-08-12       Impact factor: 12.300

9.  Medulloblastoma expresses CD1d and can be targeted for immunotherapy with NKT cells.

Authors:  Daofeng Liu; Liping Song; Vita S Brawley; Nathan Robison; Jie Wei; Xiuhua Gao; Gengwen Tian; Ashley Margol; Nabil Ahmed; Shahab Asgharzadeh; Leonid S Metelitsa
Journal:  Clin Immunol       Date:  2013-06-18       Impact factor: 3.969

10.  Amplification and overexpression of Hsa-miR-30b, Hsa-miR-30d and KHDRBS3 at 8q24.22-q24.23 in medulloblastoma.

Authors:  Yuan Lu; Sarra L Ryan; David J Elliott; Graham R Bignell; P Andrew Futreal; David W Ellison; Simon Bailey; Steven C Clifford
Journal:  PLoS One       Date:  2009-07-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.